ライフサイエンスコーパス: clinical

1 ars, and Nf-L and GFAP 4 to 8 years prior to clinical AD.

2 kers were associated with the development of clinical AD; especially, the time-specific associations

3 (GNB n = 114; SAB n = 111) were included for clinical analysis.

4 l antibody (daratumumab) was proposed with a clinical and biological response.

5 and diversify databases and pave the way for clinical and direct-to-consumer (DTC) applications.

6 ogy will serve as the new starting point for clinical and experimental purposes.

7 al tumors and their association with patient clinical and genetic characteristics.

8 We aimed to evaluate the clinical and genetic prevalence of lipodystrophy disorde

9 external validation, the CLIV Score based on clinical and immune-virological parameters is potentiall

10 ller-Hinton agar were performed according to Clinical and Laboratory Standards Institute (CLSI) guide

11 ibility testing was performed as outlined by Clinical and Laboratory Standards Institute documents M2

12 Here, we summarize clinical and preclinical findings of epigenetic alterati

13 idate to enable miniature bioelectronics for clinical and research applications.

14 We established a clinical and technical protocol for repeated home collec

15 development transitions from preclinical to clinical and theoretical to practical, that pharmacologi

16 Seizures often herald the clinical appearance of gliomas or appear at later stages

17 Because the clinical appearance of oral mucosal lesions is not an ad

18 Beyond their potential clinical application and role in tumorigenesis, recent s

19 The HLA system plays a pivotal role in both clinical applications and immunology research.

20 nd surface samples were collected from seven clinical areas, occupied by patients with COVID-19, and

21 However, most widely used clinical assays lack patient-matched control DNA and add

22 opens new avenues for accurate diagnosis and clinical assessment in individuals affected by these dis

23 rmal imaging is a promising approach for the clinical assessment of lesion activity on root surfaces.

24 After a full periodontal clinical assessment, GCF samples were collected from hea

25 Warning signs were determined based on daily clinical assessments, laboratory tests and ultrasound fi

26 g environments are emerging as complementary clinical assessments.

27 People with clonal hematopoiesis may come to clinical attention in a variety of ways, including durin

28 of 31% (14 of 45 patients; 95% CI 18-47) and clinical benefit rate of 49% (22 of 45; 34-64) in the al

29 o diminish pathologies resulting from it for clinical benefit.

30 e being developed to increase and expand the clinical benefits of these treatments in patients with d

31 were detected between lipidomic features and clinical biomarkers.

32 Data from the clinical booking system (new patient and follow-up visit

33 All rejections and clinical borderline rejections in protocol biopsies were

34 ack of precision in both neuroanatomical and clinical boundaries have likely contributed to the inabi

35 rties which led to the identification of the clinical candidate PF-06826647 (22).

36 alence of lipodystrophy disorders in a large clinical care cohort.

37 nities they offer for advancing research and clinical care, hurdles to be overcome, and the need for

38 T-CT can be safely incorporated into routine clinical care, in some cases leading to surgery with int

39 the 8th edition is expected to better drive clinical care, treatment recommendations, and future res

40 h an intact uterus were carried out at 40 US clinical centers (1993-2016).

41 Demographic and clinical characteristics and self-reported acute and per

42 PIV serotypes, few studies have compared the clinical characteristics and severity of infection among

43 We compared demographic and clinical characteristics of IC and non-IC adults using d

44 eing made worldwide to identify the specific clinical characteristics of infected critically ill pati

45 We show that DM prevalence and clinical characteristics of TB-DM vary across settings.

46 Clinical characteristics, MELD-Na, and mortality on the

47 nd current IQ showed different premorbid and clinical characteristics, which converged with broad gen

48 ophy network mapping as a method to localize clinical, cognitive, and neuropsychiatric symptoms to br

49 ellular abundance with a large, well-curated clinical cohort of PTEN-variant carriers.

50 rnessing the expertise of the biomedical and clinical communities is imperative to expand the availab

51 rtant resource for both the research and the clinical communities.

52 ions, and solicited feedback from the larger clinical community.

53 Outcomes were measured by the clinical composite score (primary efficacy end point), q

54 Enterobacteriaceae (ESBL-PE), with undefined clinical consequences.

55 omic subgroups with distinctive pathways and clinical correlates, including a group closest to HFrEF

56 The clinical correlation found that the Fusion and BioFire a

57 Charts were reviewed for clinical correlations.

58 future applications aimed at predicting the clinical course of TS in individuals over development.

59 Clinical course, slit lamp photographs, and AS OCT findi

60 erstood, and it may vary by presentation and clinical course.

61 quencing, whole-genome/exome sequencing, and clinical covariates in 134 neuroblastoma patient samples

62 This method can be applied to routine clinical CT scans acquired from patients during their AA

63 This date was set as the clinical cutoff for the primary analysis.

64 Clinical data and biological samples were obtained at ad

65 The final date of clinical data collection was December 2017.

66 These findings are supported by clinical data from ICB treatment cohorts.

67 of stress ratio were highly consistent with clinical data on bifurcation stenting.

68 Clinical data recorded were medical history, vaccination

69 Preclinical and clinical data suggest that acetyl-CoA carboxylase (ACC)

70 Demographic and clinical data were collected, including data on clinical

71 ved at later time points of white matter and clinical decline using both internal and external datase

72 of 345 participants (312 healthy and 33 with clinical depression).

73 Important patient clinical determinants of self-care included cognitive st

74 t for antibiotics and many inhibitors are in clinical development.

75 is fundamental knowledge might inform future clinical developments.

76 population was similar using genetic versus clinical diagnoses.

77 is urgently needed in many fields including clinical diagnosis and environmental microbiology, to un

78 nature identified cancer patients prior to a clinical diagnosis and was superior to alpha-fetoprotein

79 ferences that predate islet autoimmunity and clinical diagnosis may suggest a role for epigenetics in

80 R2) are the three crucial biomarkers for the clinical diagnosis of breast cancer.

81 We identified significant clinical differences but also identified important simil

82 Besides other baseline and clinical differences, EE more frequently affects prosthe

83 : 46.6 +/- 7.9; 83% females) with a range of clinical disability, who completed the 6MWT wearing gait

84 s in identifying genetic anomalies linked to clinical disease.

85 ination of Intralipid with half the standard clinical dose of Abraxane reduces the tumor growth rate

86 r growth rate as effectively as the standard clinical dose.

87 ent models: (a) 375 neuroradiologist-labeled clinical DW positive stroke cases (CDB); (b) 2000 synthe

88 Prolonging the clinical effectiveness of beta-lactams, which remain fir

89 regulated kinase 1/2 signaling; however, the clinical efficacy of inhibitors to this pathway is limit

90 Randomized, controlled trials evaluating the clinical efficacy of PCCs in patients with factor Xa inh

91 potential of a structural approach to inform clinical efforts in targeting KRAS-G12D tumors by immuno

92 edictive ability of nGA for the conventional clinical endpoint of geographic atrophy (GA) as defined

93 severity grade, HIV co-infection status, and clinical endpoints by 3 months were recorded.

94 SARS-CoV-2 in biological media, while blind clinical evaluations of 100 suspected samples furtherly

95 Current clinical evidence does not support stopping angiotensin-

96 Both basic and clinical evidence reveal dual roles for GJs, in tumor su

97 While this notion is supported by early clinical evidence, the mutation frequencies of these and

98 AI-based support across different levels of clinical expertise and multiple clinical workflows.

99 , we performed linear regression to identify clinical factors associated with myocardial injury in CO

100 stronger predictive power compared with the clinical factors model, with a minimum increase of area

101 lished in preclinical models of HCC with the clinical failure of AR antagonists in patients with adva

102 Currently, clinical FDA and European Committee on Antimicrobial Sus

103 We aimed to evaluate prevalence, staging and clinical features correlated with NAFLD among patients w

104 Clinical features from 87 patients with LEMS, occurring

105 hology, astrogliosis, neurodegeneration, and clinical features of ALS.

106 s: Six microRNA modules were associated with clinical features of asthma.

107 notherapy administration should be guided by clinical features of encephalitis, rather than autoantib

108 Because most of the clinical features of hypothyroidism are nonspecific, the

109 al history, vaccination status, type of IPD, clinical features, and short-term evolution.

110 r patients were lost to follow-up during the clinical follow-up.

111 by the combination of histology and imaging/clinical follow-up.

112 enomic medicine in these countries closer to clinical fruition.

113 enotypes continues to present a challenge to clinical geneticists and diagnostic laboratories.

114 ncers, few have been guided by biomarkers or clinical-grade assays developed to predict patient respo

115 e compliant with international standards for clinical guidelines to improve their quality and clarity

116 gnostic testing only partially predicts this clinical heterogeneity.

117 Clinical outcomes vary among youths at clinical high risk for psychosis (CHR-P), with approxima

118 Patients at clinical high-risk (CHR) for psychosis show elevations i

119 hies together with systematic assessments of clinical, histological, and immunologic parameters.

120 Allergists and clinical immunologists should have a leading role in thi

121 The European Academy of Allergy and Clinical Immunology created a task force to assess the s

122 ineage with huge strain diversity and a high clinical impact.

123 cell population in the JE and have potential clinical implications for prevention and treatment of pe

124 However, the biological and clinical implications of TP53 allelic state have not bee

125 Further research is needed to understand the clinical importance of the findings.

126 further research is needed to understand the clinical importance of the observed differences.

127 agnostic test for canine bartonelloses is of clinical importance.

128 lopment of the prediction model was based on clinical information available during ICU stay.

129 ing the lesion into a microphone, simulating clinical interpretation.

130 granulocytic production, opening venues for clinical intervention that require enhanced or reduced p

131 emergency medical services for streamlining clinical investigations and accurate triage, use of prec

132 Although the liver is the primary site for clinical islet transplantation, it poses several restric

133 One clinical isolate was killed more effectively in azithrom

134 Compared with a clinical isolate, the infectious-clone-derived SARS-CoV-

135 ed mechanisms of beta-lactam resistance, 180 clinical isolates from the Mayo Clinic and Mayo Clinic L

136 al ductal hyperplasia (ADH) is an unresolved clinical issue.

137 to control for confounders identified using clinical judgment and statistical criteria.

138 s with workload and understaffing that other clinical laboratory sections have addressed with automat

139 Clinical leukapheresis can concentrate mononuclear cells

140 ctions (5 Gy per fraction), delivered from a clinical linear accelerator.

141 Evaluation of clinical long-term results 20 years after connective tis

142 this approach warrants consideration in the clinical management of gemcitabine-refractory PDAC.

143 nical data were collected, including data on clinical management, respiratory failure, and patient mo

144 Demographic, clinical, management data (including complications), and

145 licated genes or groups of genes to the many clinical manifestations in DS.

146 Clinical microbiology laboratories face challenges with

147 t perfusate compositions in experimental and clinical models.

148 Further sub-classification of clinical-molecular correlates stratified pLGG into risk

149 itical concentrations (CCs) for categorizing clinical Mycobacterium tuberculosis isolates as suscepti

150 enotypically and genotypically characterized clinical Mycobacterium tuberculosis isolates.

151 t this practice, which does not have a clear clinical net benefit.

152 Clinical observation suggests that HIV progress more rap

153 e current work are consistent with published clinical observations and the results of previous clinic

154 Research Service Award, American Society of Clinical Oncology Young Investigator Award, MSK's Ludwig

155 beta-galactosidase (beta-Gal) deficiency and clinical onset of the neurodegenerative lysosomal storag

156 Associations of clinical or radiographic characteristics with progressio

157 s umbilical cord blood and, as part of their clinical outcome measures, were imaged with diffusion MR

158 tervention and its use is supported by large clinical outcome trials.

159 ority HIV variants on virologic response and clinical outcome.

160 hus, missing the opportunity for an improved clinical outcome.

161 , globe, lens, ciliary body) correlated with clinical outcome.

162 e a deleterious impact on multiple sclerosis clinical outcomes but it is unclear whether this is medi

163 yocardial fibrosis is a major determinant of clinical outcomes in heart failure (HF) patients.

164 t of telomere maintenance mechanism (TMM) on clinical outcomes in high-risk neuroblastoma, we integra

165 tatus changes were associated with long-term clinical outcomes in the COAPT population.

166 ngitudinal atlases and integrating them with clinical outcomes should help identify novel predictive

167 Clinical outcomes vary among youths at clinical high ris

168 Clinical parameters included patient characteristics, co

169 We characterized clinical parameters, mortality, and B cell phenotypes in

170 s for RSClin were compared with RS alone and clinical-pathological features alone using likelihood ra

171 -1/PD-L1 interaction was not correlated with clinical PD-L1 expression scores in malignant melanoma.

172 -7) has shown favorable properties regarding clinical performance and radiochemical accessibility.

173 extensively implicated in placebo effects, a clinical phenomenon thought to rely on contextual proces

174 rrier presented 2 years later with a similar clinical picture.

175 al stage, which would be of great benefit in clinical practice and a large cost-saving in clinical tr

176 trial before firm recommendations regarding clinical practice can be made.

177 In 2017, the Endocrine Society updated its clinical practice guideline for the care of transgender

178 This review aimed to identify current clinical practice guidelines worldwide, appraise their m

179 option of some of these methods into routine clinical practice in some centers.

180 ase caused by several drugs commonly used in clinical practice, herbs and dietary supplements prescri

181 HCC surveillance remains underused in clinical practice, particularly among patients with alco

182 nsolidations visualized by micro-CT alike in clinical practice.

183 plementary risk communication tool for AF in clinical practice.

184 retrospective cohort study, we describe the clinical presentation and workup of parathyroid carcinom

185 ement guidelines based on histopathology and clinical presentation, genomic classification enables ea

186 5.4% vs 45.1%; P = .005) and had less severe clinical presentations (median Pitt score, 0 [interquart

187 fferential improvement in performance on the clinical-process measure (0.22 SD; 95% CI, 0.05 to 0.38;

188 We validated the clinical profiles for all three CT signatures in the rep

189 parathyroid carcinoma (PC) and determine its clinical prognostic parameters.

190 marker, has recently drawn attention for its clinical prognostic value, although its capacity to pred

191 sonalized therapeutic approaches for slowing clinical progression of AD.

192 entifies patients at high risk for near-term clinical progression.

193 m (new patient and follow-up visits) for all clinical provider types of the multidisciplinary metabol

194 Clinical records, fundus photographs, and OCT imaging fo

195 in unexposed people; however, the source and clinical relevance of the reactivity remains unknown.

196 To validate the clinical relevance of these methods, we quantified the p

197 alues that can be universally implemented in clinical research and therapeutic trials.

198 ary use of electronic health record data for clinical research concerning allergy, asthma, and immuno

199 y systems for understanding maladaptive use, clinical research parsing what AUD patients remember fro

200 s at risk remains limited despite decades of clinical research.

201 Independent baseline predictors of clinical responder status were lower serum creatinine an

202 with cancer immunotherapy to further improve clinical response and toxicity profiles has grown.

203 terval {CI}, -11.9% to 1.2%]), and favorable clinical response at early follow-up was 61.0% and 55.8%

204 T cell infiltration were not associated with clinical response, we discovered numerous chromosomal al

205 that they are able to provide their primary clinical responsibilities for ophthalmic care independen

206 ase has been demonstrated by both the robust clinical responsiveness of IgG4-RD to B cell depletion a

207 Despite the outstanding clinical results of immune checkpoint blockade (ICB) in

208 ementary useful information to the available clinical risk factors.

209 e normal, appears to associate with elevated clinical risk.

210 andheld swept-source (SS) OCT at the time of clinical ROP examinations.

211 rature on the implementation of radiomics in clinical routine chest CT scans.

212 We analyzed 194 clinical S. Typhi, temporal representatives from those i

213 a panel of more than 100 well-characterized clinical samples diagnosed and confirmed using a previou

214 that used the Primer-ID method have analyzed clinical samples directly.

215 ication of such methods to broadly available clinical samples such as formalin-fixed and paraffin-emb

216 of metagenomic sequencing data obtained from clinical samples using R9.4.1 Nanopore sequencing.

217 chieved >99% 5-fold genome coverage (in 9/20 clinical samples).

218 In 4 of the 141 clinical samples, the BCID-FP panel correctly identified

219 ustered in two groups displaying high or low clinical scores.

220 The clinical sensitivity in detecting active subarachnoid or

221 und that increased plasma IFN-gamma in early clinical sepsis was associated with the later developmen

222 ly activated and become dysfunctional during clinical sepsis, and contribute to tissue-specific cytok

223 alth services research that the provision of clinical services to individuals is not a viable approac

224 ture injuries as seen in a military relevant clinical setting and a realistic approach for assessing

225 Bacterial resistance to antibiotics in this clinical setting further underlines the need for develop

226 ic estimates, which are swift to derive in a clinical setting, will allow for the investigation of ca

227 y resulting from uncontrollable factors in a clinical setting.

228 studies with regards to patient population, clinical settings, and outcomes examined.

229 nd wireless transmission in many medical and clinical settings.

230 We explored the clinical significance and predictive value of trans-ethn

231 In pigs challenged by gavage with HEWP, clinical signs were noted in 5/6 pigs including diarrhoe

232 R-CAP could well be 'axonal CIDP' in view of clinical similarity, but not proven as yet.

233 e largest German cohort observed by a single clinical site.

234 tion of glycopeptides and phosphopeptides in clinical specimens, cell lysates, and mouse liver tissue

235 the presence of amyloid positivity in the AD clinical spectrum and amyloid Tg rat model.

236 ic and prognostic tool for AD, regardless of clinical stage, which would be of great benefit in clini

237 a preclinical PERCIST paradigm to complement clinical standards.

238 Despite numerous clinical studies, outcomes are consistently disappointin

239 (multidrug and toxin extrusion proteins) in clinical studies.

240 ith the longitudinal data from two published clinical studies.

241 dulator that has been evaluated in a phase 2 clinical study for the treatment of Duchenne muscular dy

242 Our recent clinical study suggested that polyphenol-rich purple pot

243 An impressive clinical success has been observed in treating a variety

244 Biomarkers or specific clinical symptoms to identify PTLDS patients do not curr

245 en resistance in prostate cancer amenable to clinical testing using available targeted therapies.

246 how PARP inhibitors have emerged as a novel clinical therapy to treat homologous recombination-defic

247 tion in cardiovascular diseases, attempts at clinical translation have shown mixed results.

248 ch, could therefore offer key advantages for clinical translation.

249 nanoparticles for nanomedicine and eventual clinical translation.

250 Analysis of clinical transplantation data linked low circulating lev

251 We did an open-label, randomised clinical trial at 57 centres in Brazil.

252 NG, AND PARTICIPANTS: Open-label, randomized clinical trial conducted at 17 UK hospitals.

253 We present evidence that a clinical trial examining the effects of metformin on cog

254 clinical practice and a large cost-saving in clinical trial recruitment.

255 tivity analyses using different estimates of clinical trial success rates, preclinical expenditures,

256 report negative results on a randomized clinical trial testing the combination of apremilast, a

257 mized 40 SCZ non-smokers into a double-blind clinical trial with four groups: placebo, 5 mg/d, 10 mg/

258 In this parallel-group, double-blind clinical trial, participants were randomized to receive

259 bling the recruitment process for the target clinical trial, which then can be used for augmenting th

260 ntly, a peptidomimetic inhibitor has entered clinical trial; however, small-molecule orally available

261 ons) and in a systematically selected set of clinical trials (accuracy > 84% for predicting statistic

262 s (n = 116) enrolled in 3 phase-3 randomized clinical trials (AMAGINE -1 [Efficacy, Safety, and Withd

263 esearch on NIRF nanoprobes has translated to clinical trials and it will further translate to cancer

264 sights into the limited activity of HDACi in clinical trials and offers direction for future approach

265 effectiveness is consistent with efficacy in clinical trials and supports current recommendations tha

266 Although clinical trials for Stargardt are currently underway, th

267 ssed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322).

268 Though several hundred clinical trials have tested immune-based approaches in c

269 options for metastatic UM are limited, with clinical trials having little impact.

270 rs and scientists have initiated hundreds of clinical trials in an expedited effort to understand, pr

271 lockade (ICB) in melanoma and other cancers, clinical trials in breast cancer have reported low respo

272 are currently being evaluated in early phase clinical trials in children with high-risk MYCN-driven d

273 lls (PBMC) RNA from subjects enrolled in the Clinical Trials in Organ Transplantation-09 study in whi

274 At least 2 prospective clinical trials involving (177)Lu-PSMA agents are under

275 drug development, testing and progression to clinical trials is overwhelmingly expensive.

276 in this review, of which 12 were randomized clinical trials of therapy that included 3074 patients,

277 Clinical trials of typhoid conjugate vaccine (TCV) are o

278 ctivation in tumor progression, results from clinical trials of various AKT inhibitors remain subopti

279 This study is registered with the EU Clinical Trials Register (EudraCT 2010-022134-89).

280 ld-based nanodevices are currently tested in clinical trials, and none of them are approved by health

281 In an open label clinical trials, participants with ASD were administered

282 nd Na(V)1.8-specific blockers have undergone clinical trials, with others in preclinical development,

283 all IRAE rates for comparison with published clinical trials.

284 tment on SB and colonic ACE2 expression in 3 clinical trials.

285 re being evaluated in endocrine-resistant BC clinical trials.

286 cal observations and the results of previous clinical trials.

287 future research questions and direct future clinical trials.

288 al review discusses how the need for reduced clinical turnaround times has influenced chemical instru

289 effects in the presence of ART prevent their clinical use and call for different Treg depletion appro

290 eight ADCs and two immunotoxins approved for clinical use.

291 all these factors, the data used to consider clinical utility must be derived from level I evidence s

292 ased interest in understanding the potential clinical utility of a genetic predictor that might furth

293 markers of neurological damage with possible clinical utility, many of which whose presence in blood

294 cine, however, has not fully translated into clinical utilization and patient benefits due to issues

295 157 unique subjects participated in home and clinical visits and of these, 93 completed a 6-month fol

296 aken using an online parental questionnaire, clinical visits including structured interviews and skin

297 d at least 2 good-quality SD-OCT scans and 2 clinical visits with Goldmann applanation tonometry were

298 93 completed a 6-month follow-up of home and clinical visits.

299 nt levels of clinical expertise and multiple clinical workflows.

300 izations (SDs) and seizures, known agents of clinical worsening after TBI.